Bioventus Q4 Results Beat Market; Sees FY25 Earnings, Sales Above Street; Stock Climbs In Pre-market

(RTTNews) - Bioventus Inc. (BVS), a medical device company, on Tuesday reported narrower net loss in its fourth quarter with higher revenues. Adjusted earnings and top line beat market estimates. Further, the company issued fiscal 2025 outlook, expecting earnings and sales above the Street.

In pre-market activity on the Nasdaq, Bioventus shares were gaining around 22.4 percent to trade at $10.72. On Monday's regular trading, the shares had closed 5 percent lower at $8.76.

For the fourth quarter, net loss attributable to the company was $0.17 million, compared to prior year's net loss of $6.10 million.

Net loss from continuing operations was $0.32 million, compared to net loss of $7.66 million in the prior-year period.

There was no loss per share of Class A common stock in the latest quarter, compared to a loss of $0.10 per share last year.

Adjusted earnings per share from continuing operations was $0.15 per share, compared to income of $0.07 per share in the prior year.

For the fourth quarter, worldwide revenue totaled $153.64 million, an increase of 13.5 percent from prior year's $135.42 million, driven by double-digit growth in Pain Treatments and Surgical Solutions.

The Wall Street analysts on average expected the company to report $0.08 per share on revenues of $145.16 million. Analysts' estimates typically exclude special items.

Total U.S. net sales grew 13.8 percent to $135.21 million and International sales went up 11 percent to $18.43 million.

Looking ahead, Rob Claypoole, Bioventus President and Chief Executive Officer, said, "....we are well positioned to build on this positive momentum, driving above-market revenue growth with a multitude of diverse growth drivers, while enhancing profitability and accelerating cash flow.."

For fiscal 2025, the company projects adjusted earnings per share of $0.64 to $0.68, reflecting an increase of 30.6 percent to 38.8 percent.

Net sales would be $560 million to $570 million, representing an organic growth of approximately 6.1 percent to 8.0 percent.

The Street is looking for earnings of $0.55 per share on sales of $554.78 million for the year.

Adjusted EBITDA is projected to be $112 million to $116 million, reflecting 100 basis points in Adjusted EBITDA Margin growth.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.